Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Doravirine
Подписчиков: 0, рейтинг: 0
Not to be confused with drotaverine.
Clinical data | |
---|---|
Trade names | Pifeltro |
Other names | MK-1439 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618048 |
License data |
|
Routes of administration |
By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.454 |
Chemical and physical data | |
Formula | C17H11ClF3N5O3 |
Molar mass | 425.75 g·mol−1 |
3D model (JSmol) | |
| |
|
Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
Doravirine was approved for medical use in the United States in August 2018.
External links
- "Doravirine". Drug Information Portal. U.S. National Library of Medicine.